Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 57 of 57 entries

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	resistant	Gilteritinib	Case Reports/Case Series	Actionable	In a Phase I trial, three patients with acute myeloid leukemia harboring FLT3 ITD with FLT3 F691L were resistant to Xospata (gilteritinib) (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	MRX-2843	Preclinical - Cell line xenograft	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant acute myeloid leukemia cells harboring FLT3 internal tandem duplication (ITD) and F691L in culture, and prolonged survival in cell line xenograft models (PMID: 27158668).	27158668
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FF-10101 inhibited Flt3 autophosphorylation and growth of leukemic cell lines and inhibited growth of cell line xenografts with FLT3-ITD/F691L compound mutations (PMID: 29187377).	29187377
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	Dubermatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Dubermatinib (TP-0903) treatment decreased phosphorylation of Flt3 and Stat5 and inhibited growth of transformed cells expressing a FLT3-ITD mutation and FLT3 F691L in culture, and reduced peripheral blood tumor burden in cell line xenograft models (PMID: 33268594).	33268594
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	LT-171-861	Preclinical - Cell line xenograft	Actionable	In a preclinical study, LT-171-861 inhibited cell viability and decreased FLT3 phosphorylation in transformed cells expressing a FLT3-ITD mutation and FLT3 F691L in culture, and inhibited tumor growth and prolonged survival in cell line xenograft models (PMID: 33391463).	33391463
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	resistant	Crenolanib + Sorafenib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, FLT3 F691L was identified as a secondary resistance mutation in FLT3 ITD-positive acute myeloid leukemia cell line xenograft models that progressed on the combination of Crenolanib (CP-868596) and Nexavar (sorafenib) (PMID: 35344039).	35344039
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	predicted - sensitive	Tuspetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Tuspetinib (HM43239) treatment resulted in tumor regression in a cell line xenograft model of acute myeloid leukemia expressing a FLT3 ITD mutation and FLT3 F691L (Cancer Res 2021;81(13_Suppl):Abstract nr 1257).	detail...
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	Sitravatinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Sitravatinib (MGCD516) inhibited proliferation of transformed hematologic cells expressing a FLT3-ITD mutation with FLT3 F691L in culture, and increased the median survival to 26 days vs 14.5 days in the vehicle-treated group in a cell line xenograft model (PMID: 36691065).	36691065
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	predicted - sensitive	PHI-101	Preclinical - Cell line xenograft	Actionable	In a preclinical study, PHI-101 decreased leukemia burden in a cell line xenograft model expressing FLT3 F691L in the context of a FLT3-ITD mutation (Blood (2020) 136 (Supplement 1): 802).	detail...
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Quizartinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, cells expressing FLT3-ITD and FLT3 F691L were resistant to treatment with Vanflyta (quizartinib) in culture and in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Gilteritinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Xospata (gilteritinib) was not active against cells expressing FLT3-ITD with FLT3 F691L in culture and resulted in minimal survival benefit in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	Foretinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Foretinib (GSK1363089) inhibited viability of cultured cells expressing FLT3-ITD with FLT3 F691L, and inhibited tumor cell growth in a cell line xenograft model (PMID: 38231480).	38231480
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	Ningetinib	Preclinical - Cell line xenograft	Actionable	In a preclinical study, Ningetinib (CT053PTSA) decreased leukemic burden in a cell line xenograft model of acute myeloid leukemia harboring a FLT3-ITD and expressing FLT3 F691L (PMID: 38978049).	38978049
FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing FLT3 ITD and F691L in culture (PMID: 27780853).	27780853
FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Nexavar (sorafenib) in culture (PMID: 23392356).	23392356
FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells over expressing FLT3 ITD and F691L were resistant to Vanflyta (quizartinib) in culture (PMID: 23392356).	23392356
FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	MRX-2843	Preclinical - Cell culture	Actionable	In a preclinical study, MRX-2843 inhibited Flt3 signaling, resulted in growth inhibition in Quizartinib (AC220)-resistant transformed cells over expressing both FLT3 internal tandem duplication (ITD) and F691L in culture (PMID: 27158668).	27158668
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	decreased response	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Lestaurtinib (CEP-701) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).	detail...
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	decreased response	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring a FLT3 internal tandem duplication and expressing FLT3 F691L demonstrated a decreased response to Rydapt (midostaurin) compared to treated cells harboring a FLT3 ITD and expressing FLT3 Y842C (Blood 2009 114:3776).	detail...
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	SKI-G-801	Preclinical - Cell culture	Actionable	In a preclinical study, cells co-expressing a FLT3 internal tandem duplication and FLT3 F691L were sensitive to SKI-G-801 in culture, demonstrating inhibition of cell growth and inhibition of Flt3 autophosphorylation (PMID: 24532805).	24532805
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	CG-806	Preclinical - Cell culture	Actionable	In a preclinical study, CG-806 inhibited proliferation of a cell line expressing a FLT3 exon 14 insertion (ITD) mutation and FLT3 F691L in culture (PMID: 35499387).	35499387
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	predicted - resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Crenolanib-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).	31309543
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Vanflyta (quizartinib)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).	31309543
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Xospata (gilteritinib)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).	31309543
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, Rydapt (midostaurin) did not inhibit growth of transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L in culture (PMID: 31309543).	31309543
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were resistant to Nexavar (sorafenib)-induced growth inhibition in culture (PMID: 31309543).	31309543
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	decreased response	Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing both FLT3 exon 14 insertions (ITD) and FLT3 F691L were less sensitive to Ayvakit (avapritinib)-induced growth inhibition compared to cells expressing FLT3 ITD in culture (PMID: 31309543).	31309543
FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	LAM-003	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 internal tandem duplication (ITD) and FLT3 F691L demonstrated sensitivity to LAM-003 treatment in culture (PMID: 31751472).	31751472
FLT3 exon 14 ins FLT3 F691L	myeloid leukemia	resistant	A-419259	Preclinical - Cell culture	Actionable	In a preclinical study, transformed myeloid leukemia cells co-expressing FLT-ITD and FLT3 F691L demonstrated resistance to A-419259 treatment in culture (PMID: 31790499).	31790499
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	KW-2449	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells co-expressing FLT3 ITD and FLT3 F691L were resistant to treatment with KW-2449 in culture (PMID: 22858906).	22858906
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Momelotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Momelotinib (CYT387) in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to treatment with Xospata (gilteritinib) in culture (PMID: 33780043).	33780043
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	predicted - resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to treatment with Crenolanib in culture (PMID: 33780043).	33780043
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to treatment with Vanflyta (quizartinib) in culture (PMID: 33780043).	33780043
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to treatment with Rydapt (midostaurin) in culture (PMID: 33780043).	33780043
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring FLT3-ITD and FLT3 F691L demonstrated sensitivity to treatment with FF-10101 in culture, but were less sensitive compared to cells harboring FLT3-ITD alone (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	FF-10101	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells harboring FLT3-ITD and FLT3 F691L demonstrated sensitivity to treatment with FF-10101 in culture, but were less sensitive compared to cells expressing FLT3-ITD alone (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3 ITD with FLT3 F691L demonstrated resistance to treatment with Xospata (gilteritinib) in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	resistant	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring FLT3 ITD with FLT3 F691L were resistant to Xospata (gilteritinib) in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, acute myeloid leukemia cells harboring FLT3 ITD with FLT3 F691L were resistant to Vanflyta (quizartinib) in culture (PMID: 32040554).	32040554
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 F691L were moderately resistant to Xospata (gilteritinib) treatment in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Quizartinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 F691L were resistant to Vanflyta (quizartinib) treatment in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Midostaurin	Preclinical - Cell culture	Actionable	In a preclinical study, transformed hematologic cells expressing FLT3-ITD and FLT3 F691L were moderately resistant to Rydapt (midostaurin) treatment in culture (PMID: 35395091).	35395091
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Lestaurtinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Lestaurtinib (CEP-701) in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	resistant	Sorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Nexavar (sorafenib) in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	conflicting	Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L demonstrated resistance to Vonjo (pacritinib) in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	predicted - resistant	Crenolanib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing FLT3-ITD and FLT3 F691L, and FLT3 D835Y were resistant to Crenolanib (CP-868596) in culture (PMID: 34768286).	34768286
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	conflicting	Pacritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Vonjo (pacritinib) inhibited phosphorylation of Flt3 and Stat5 and viability in a transformed cell line expressing a FLT3-ITD mutation and FLT3 F691L in culture (PMID: 31102119).	31102119
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	PLM-101	Preclinical - Cell culture	Actionable	In a preclinical study, PLM-101 inhibited proliferation in cells expressing FLT3 F691L in the context of a FLT3-ITD mutation in culture (PMID: 37392657).	37392657
FLT3 exon 14 ins FLT3 F691L	acute myeloid leukemia	sensitive	RMC-4550	Preclinical - Cell culture	Actionable	In a preclinical study, RMC-4550 inhibited viability in an acute myeloid leukemia cell line harboring FLT3 ITD and expressing FLT3 F691L in culture (PMID: 37992684).	37992684
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	predicted - sensitive	PHI-101	Preclinical - Biochemical	Actionable	In a preclinical study, PHI-101 demonstrated activity against FLT3 F691L in the context of a FLT3-ITD mutation in culture (Cancer Res 2020;80(16 Suppl):Abstract nr 4226).	detail...
FLT3 exon 14 ins FLT3 F691L	Advanced Solid Tumor	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited growth of transformed cells expressing a compound FLT3 F691L/FLT3-ITD mutation in culture (PMID: 25847190).	25847190
FLT3 exon 14 ins FLT3 F691L	leukemia	sensitive	Pexidartinib	Preclinical	Actionable	In a preclinical study, PLX3397 inhibited proliferation of human leukemia cells harboring both FLT3-ITD and FLT3 F691L in culture (PMID: 25847190).	25847190
FLT3 exon 14 ins FLT3 F691L	leukemia	sensitive	E6201	Preclinical	Actionable	In a preclinical study, E6201 inhibited proliferation and induced apoptosis in FLT3 inhibitor-resistant leukemia cell lines harboring FLT3 F691L in addition to FLT3 internal tandem duplications (ITD) in culture (PMID: 26822154).	26822154
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	predicted - sensitive	Tuspetinib	Preclinical	Actionable	In a preclinical study, Tuspetinib (HM43239) treatment inhibited transformed cells expressing FLT3 ITD and F691L in cell culture (Cancer Res 2019;79(13 Suppl):Abstract nr 1293).	detail...
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	KX2-391	Preclinical	Actionable	In a preclinical study, KX2-391 treatment inhibited viability, decreased downstream signaling, and induced apoptosis in cells expressing a FLT3-ITD mutation with FLT3 F691L in culture, and inhibited tumor growth and prolonged survival in mouse models (PMID: 34217323).	34217323
FLT3 exon 14 ins FLT3 F691L	hematologic cancer	sensitive	Ningetinib	Preclinical	Actionable	In a preclinical study, Ningetinib (CT053PTSA) inhibited Flt3 downstream signaling and viability in a cell line expressing a FLT3-ITD and FLT3 F691L in culture and decreased leukemic burden and prolonged survival in a mouse model (PMID: 38978049).	38978049

Showing 1 to 57 of 57 entries

Filter rows:

Profile Name	FLT3 exon 14 ins FLT3 F691L
Gene Variant Detail	FLT3 exon 14 ins (gain of function - predicted) FLT3 F691L (no effect - predicted)
Relevant Treatment Approaches

Molecular Profile Detail

Contact

Filtering

Sorting